Cerebral Palsy, Spastic Clinical Trial
Official title:
Muscle-tendon Pathology, Metabolic Dysregulation and Chronic Inflammation in Adolescents and Young Adults With Moderate to Severe Spastic Cerebral Palsy
The main aim of this project is to gain knowledge about the muscle-tendon pathology of moderately to severely affected young people with cerebral palsy and their risk for cardiometabolic diseases and chronic inflammation. Furthermore, it will be investigated whether there are associations between the existing pathophysiology as well as inactivity and muscle function, cardiometabolic risk factors and inflammation. Moreover, the potential of the target group for adaptation of its muscular, cardiorespiratory, and endocrine system will be investigated. The study parameters will be determined in adolescents and young adults aged 14 to 25 years with moderate to severe spastic cerebral palsy and compared with those of their less severely affected and healthy peers (cross-sectional study). In addition, the more affected individuals will participate in a 12-week training intervention (longitudinal study) performed with special tricycles (i.e., Frame Runners). To measure the study parameters, ultrasound, strength tests, near-infrared spectroscopy, blood analyses, and spiroergometry will be used. The fitness training will be performed two times a week for 12 weeks with the Frame Runners.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 14 Years to 25 Years |
Eligibility | Inclusion Criteria: - spastic cerebral palsy - mildly, moderately or severly affected (Gross Motor Function Classification System level I-IV) - age range 14 - 25 years - ability to accept and follow verbal instructions - strong communication skills - sufficient vision (visual function that enables safe movement with reference to people and obstacles) - less than 15 hours of experience with the Frame Runners; healthy peers in the same age range Exclusion Criteria: - other forms of cerebral palsy - orthopaedic surgery in the last 12 months - Botulinum toxin application in the last 6 months |
Country | Name | City | State |
---|---|---|---|
Austria | Institute of Human Movement Science, Sport and Health, University of Graz | Graz |
Lead Sponsor | Collaborator |
---|---|
University of Graz | Karolinska Institutet, Medical University of Graz |
Austria,
Bell KJ, Ounpuu S, DeLuca PA, Romness MJ. Natural progression of gait in children with cerebral palsy. J Pediatr Orthop. 2002 Sep-Oct;22(5):677-82. — View Citation
Graham HK, Rosenbaum P, Paneth N, Dan B, Lin JP, Damiano DL, Becher JG, Gaebler-Spira D, Colver A, Reddihough DS, Crompton KE, Lieber RL. Cerebral palsy. Nat Rev Dis Primers. 2016 Jan 7;2:15082. doi: 10.1038/nrdp.2015.82. — View Citation
Howard JJ, Herzog W. Skeletal Muscle in Cerebral Palsy: From Belly to Myofibril. Front Neurol. 2021 Feb 18;12:620852. doi: 10.3389/fneur.2021.620852. eCollection 2021. — View Citation
Narayanan UG, Fehlings D, Weir S, Knights S, Kiran S, Campbell K. Initial development and validation of the Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD). Dev Med Child Neurol. 2006 Oct;48(10):804-12. doi: 10.1017/S0012162206001745. — View Citation
Nooijen CF, Slaman J, Stam HJ, Roebroeck ME, Berg-Emons RJ; Learn2Move Research Group. Inactive and sedentary lifestyles amongst ambulatory adolescents and young adults with cerebral palsy. J Neuroeng Rehabil. 2014 Apr 3;11:49. doi: 10.1186/1743-0003-11-49. — View Citation
Verschuren O, Peterson MD, Balemans AC, Hurvitz EA. Exercise and physical activity recommendations for people with cerebral palsy. Dev Med Child Neurol. 2016 Aug;58(8):798-808. doi: 10.1111/dmcn.13053. Epub 2016 Feb 7. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Body height | cm | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Other | Body weight | kg | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Other | Body mass index (BMI) | Body height and weight will be combined to calculate the BMI in kg/m^2 | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Other | Modified Ashworth Scale Score of the Plantar flexors | number | Group 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Primary | Muscle fascicle length and muscle thickness | cm | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Primary | Muscle fascicle pennation angle | degrees | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Primary | Passive muscle stiffness | kilopascal (kPa) | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Primary | Isometric muscle strength | kg | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Primary | Muscle tissue oxygenation | Tissue saturation index (TSI) | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Primary | Exosome size | nanometers (nm) | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Primary | Exosome content | number/ml | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Primary | Micro ribonucleic acid (RNA) cargo | expression level | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Secondary | Metabolic parameters | Glucose, C-peptide, free fatty acids, cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein in mmol/l | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Secondary | Pro-inflammatory cytokines | e.g., Interleukin 6, tumor necrosis factor alpha in pg/ml | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Secondary | Resting, mean, and peak heart rate | beats/min | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), measurement after 6 weeks of training (T1_6weeks, 20 weeks), post-measurement (T2, 27 weeks) | |
Secondary | Resting blood pressure | mmHg | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Secondary | Distance covered | m | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), measurement after 6 weeks of training (T1_6weeks, 20 weeks), post-measurement (T2, 27 weeks) | |
Secondary | Peak oxygen uptake (VO2peak), Peak ventilation (VEpeak) | l/min | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), measurement after 6 weeks of training (T1_6weeks, 20 weeks), post-measurement (T2, 27 weeks) | |
Secondary | Peak respiratory frequency | breaths/min | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), measurement after 6 weeks of training (T1_6weeks, 20 weeks), post-measurement (T2, 27 weeks) | |
Secondary | Respiratory exchange ratio | peak carbon dioxide production (VCO2peak)/VO2peak | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), measurement after 6 weeks of training (T1_6weeks, 20 weeks), post-measurement (T2, 27 weeks) | |
Secondary | VEpeak/VO2peak | ratio | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), measurement after 6 weeks of training (T1_6weeks, 20 weeks), post-measurement (T2, 27 weeks) | |
Secondary | VEpeak/VCO2peak | ratio | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), measurement after 6 weeks of training (T1_6weeks, 20 weeks), post-measurement (T2, 27 weeks) | |
Secondary | Perceived exertion | 6-20 Borg Scale | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), measurement after 6 weeks of training (T1_6weeks, 20 weeks), post-measurement (T2, 27 weeks) | |
Secondary | Well-being and quality of life | Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD™) questionnaire | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Secondary | Total physical activity, time spent in different intensities | min | Group 1 & 2: within 1 week between familiarisation and baseline (T0); Group 3: within 1 week after baseline (T0), within 1 week after post-measurement (T2, 28 weeks) | |
Secondary | Passive range of motion (sagittal plane) of hip, knees, ankles | degrees | Group 1 & 2: baseline (T0); Group 3: baseline (T0), pre-measurement (T1, 13 weeks), post-measurement (T2, 27 weeks) | |
Secondary | Step count | number | Group 1 & 2: within 1 week between familiarisation and baseline (T0); Group 3: within 1 week after baseline (T0), within 1 week after post-measurement (T2, 28 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04530955 -
Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)
|
N/A | |
Not yet recruiting |
NCT05131724 -
Effectiveness of Virtual Reality on Functional Mobility During Treadmill Training in Children With Cerebral Palsy
|
N/A | |
Completed |
NCT03005938 -
Influence of the Spinal Manipulation on Muscle Spasticity and Manual Dexterity in Cerebral Palsy.
|
N/A | |
Completed |
NCT04087330 -
Whole-body Vibration in Spastic Hemiplegic Cerebral Palsy
|
N/A | |
Completed |
NCT04570358 -
Stretching in Children and Adolescents With Spastic Cerebral Palsy
|
N/A | |
Completed |
NCT05945953 -
Incentive Spirometer as a Visual Feedback in Children With Spastic Cerebral Palsy
|
N/A | |
Completed |
NCT03209310 -
The Effect of Trunk Control on Respiratory Muscle Strength
|
N/A | |
Recruiting |
NCT03361930 -
Changes in Muscle Activity of Children With Spastic Unilat Cerebral Palsy Using 2 Types of Ankle-foot Orthoses to Walk
|
N/A | |
Recruiting |
NCT05593887 -
Late-presenting Hip Dislocation in Non-ambulatory Children With Cerebral Palsy: A Comparison of Three Procedures
|
N/A | |
Recruiting |
NCT03677843 -
Multidimensional Approach in Patients With Severe Cerebral Palsy, Prospective Cohort(MAPCP Cohort)-Offline
|
||
Recruiting |
NCT03179241 -
Outcome After Selective Dorsal Rhizothomy Concerning Life Quality, Cerebral Imaging and Cognition
|
||
Not yet recruiting |
NCT06434246 -
Effect of Pully System on Hemiplegic Children
|
N/A | |
Recruiting |
NCT05627921 -
The Effect of Botulinum Toxin and ESWT Applications on Spasticity and Functionality in Cerebral Palsy Patients
|
N/A | |
Completed |
NCT05102955 -
Turkish Validity and Reliability of the Visual Function Classification System (VFCS)
|
||
Completed |
NCT05251519 -
The Efficacy of Derotation Banding on Outcome Measures in Children With Cerebral Palsy
|
N/A | |
Completed |
NCT05251532 -
The Efficacy of Distortion Banding on Outcome Measures in Children With Cerebral Palsy
|
N/A | |
Completed |
NCT05115695 -
The Effect of Upper Extremity Strengthening on Functionality, Muscle Strength and Trunk in Children With Cerebral Palsy
|
N/A | |
Completed |
NCT04240275 -
Reliability of a Body-worn Sensor System for Gait Analysis in Children With CP
|
||
Not yet recruiting |
NCT05198921 -
The Effectiveness of Repetitive Transcranial Magnetic Stimulation for Spastic Diplegia Cerebral Palsy
|
N/A | |
Completed |
NCT03212846 -
Muscle Spasticity Reduction in Children With Cerebral Palsy by Means of Hippotherapy
|
N/A |